Pancreatic Cancer Research

ResearcherUniversity of SienaActive in the last 2 years

Giandomenico Roviello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5504-8237; OpenAlex author ID A5037756908. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper

Papers 12

  1. Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients. Last author DOI 10.1016/j.pan.2024.03.004↗
  2. Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine. Co-author DOI 10.1080/1120009x.2023.2190712↗
  3. Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer. First author DOI 10.2217/fon-2023-0137↗
  4. The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. Last author DOI 10.1038/s41598-022-12214-4↗
  5. Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. Last author DOI 10.1159/000524868↗
  6. Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer. Co-author DOI 10.2174/1389201023666220307090450↗
  7. Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-020-76465-9↗
  8. Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis o… Co-author DOI 10.1080/08830185.2020.1776274↗
  9. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. Last author DOI 10.2147/cmar.s267393↗
  10. Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. First author DOI 10.2174/1568009620999200918122426↗
  11. Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0219566↗
  12. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. First author DOI 10.1007/s00280-015-2683-1↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martina Catalano · 9 shared papers, 2020–2024 · strength 1.48
  2. Roberto Petrioli · 9 shared papers, 2015–2023 · strength 1.35
  3. Monica Ramello · 8 shared papers, 2020–2023 · strength 1.29
  4. Giuseppe Aprile · 4 shared papers, 2022–2023 · strength 0.74
  5. Alberto D’Angelo · 5 shared papers, 2019–2023 · strength 0.61
  6. Enrico Mini · 3 shared papers, 2020–2023 · strength 0.39
  7. Filippo Nozzoli · 1 shared paper, 2024 · strength 0.20
  8. Zahra Madjd Jabari · 1 shared paper, 2020 · strength 0.12
  9. Maryam Sahlolbei · 1 shared paper, 2020 · strength 0.12
  10. Jafar Kiani · 1 shared paper, 2020 · strength 0.12
  11. Navid Sobhani · 1 shared paper, 2019 · strength 0.09
  12. Stefan Bagby · 1 shared paper, 2019 · strength 0.09
  13. Daniele Generali · 1 shared paper, 2019 · strength 0.09
  14. Daniele Marrelli · 1 shared paper, 2015 · strength 0.06
  15. Edoardo Francini · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.